Bringing Clarity To The Supplement & Pharmaceutical Industry
Why use Zygos?
Zygos enables users to quickly assess the potential biological activity of a supplement or pharmaceutical—even when published research is limited. It does this by using advanced AI models to analyze how the arrangement of atoms within a molecule affects its interaction with the human body.
To start making predictions, all you need is the molecule’s SMILES notation. SMILES (Simplified Molecular Input Line Entry System) is a way to represent a chemical structure using plain text—just letters, numbers, and symbols. Think of it as a kind of chemical shorthand or “sentence” that shows how the atoms are connected, making it easy for computers (or chemists) to interpret.
Zygos uses this information to predict how strongly the molecule binds to various biological targets, such as receptors, in units of pKi. You can think of a molecule as a key and a protein target—like a receptor or enzyme—as a lock. The pKi value tells you how well the key fits and stays in the lock. A higher pKi means stronger binding to the target. A lower pKi indicates weaker binding.
This is important because strong binding (high pKi) to a disease-related target can help a molecule effectively block or activate that target, potentially leading to therapeutic effects. For investors in the pharmaceutical sector, this technology provides a competitive edge by rapidly screening compounds, firms can prioritize the most promising candidates, to shorten development timelines.
Neural networks are transforming the pharmaceutical industry by enabling more efficient analysis of complex molecular structures and interactions. NNs excel at modelling the relational data inherent in molecular graphs, allowing for accurate predictions of pharmaceutical properties, interactions, and efficacy.
This accelerates medicine discovery, reduces costs, and enhances the development of personalized medicine by uncovering insights that were previously unattainable through traditional methods.
You can read about some of Zygos predictions for common pharmaceuticals here.
